One of such is imatinib mesylate (GleevecTM), the inhibitor of the Abelson tyrosine-protein kinase 1 (ABL1) used to treat chronic myeloid leukemia [1], inhibitors of the mammalian target of rapamycin (mTOR) [2], phosphatidylinositol 3-kinase (PI3K; [3]), or newly discovered pyrazolopyrimidine-based GTPase inhibitors of K-Ras (Kirsten sarcoma virus protein) [4]. The gene discussed is MTOR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.